Case Note & Summary
The case involved an appeal by a pharmaceutical company against prosecution proceedings initiated by a Drug Inspector under the Drugs and Cosmetics Act, 1940. The events leading to the litigation began on April 30, 1998, when a Drug Inspector purchased a drug sample from a retailer, which was later found to be misbranded and adulterated. A complaint was filed against the manufacturer and others, leading to charges being framed against the appellants. The appellants contended that the prosecution was invalid as they did not receive a portion of the sample, violating Section 23(4)(iii) of the Act. The Sessions Court upheld some charges but dismissed the argument regarding the sample. The High Court also rejected the appellants' petition challenging the prosecution. The appellants argued that the lack of a sample deprived them of the right to contest the Government Analyst's report, which they claimed was unfair and violated their constitutional rights. The court analyzed the statutory provisions, concluding that while the report of the Government Analyst is conclusive, the manufacturer must still have avenues to challenge it, even without a sample. The court emphasized the need for a fair trial and the importance of allowing the accused to contest evidence against them. Ultimately, the Supreme Court dismissed the appeal, affirming the prosecution's validity and the interpretation of the relevant provisions of the Act.
Headnote
A) Criminal Law - Prosecution under Drugs and Cosmetics Act - Non-supply of sample - Non-supply of a portion of the sample to the manufacturer does not invalidate the prosecution - Drugs and Cosmetics Act, 1940, Sections 23, 25 - The court held that the manufacturer must have the right to challenge the report of the Government Analyst through other means, even if not supplied with a sample, ensuring compliance with Article 21 of the Constitution (Paras 1-7).
Issue of Consideration
Whether the non-supply of a sample portion to the manufacturer affects the maintainability of the prosecution under the Drugs and Cosmetics Act, 1940.
Final Decision
The Supreme Court dismissed the appeal, affirming the validity of the prosecution under the Drugs and Cosmetics Act, 1940, and emphasizing the need for the manufacturer to have means to challenge the evidence against them.
Law Points
- conclusiveness of evidence
- rights of accused
- compliance with statutory provisions
- interpretation of legislative intent
